Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

by Seini Moimoi | Sep 26, 2023 | Portfolio News

Patients Receiving Somatus Transitions of Care Assessment Services 49% Less Likely to Experience Hospital Readmission

by Seini Moimoi | Sep 26, 2023 | Portfolio News

89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

by Seini Moimoi | Sep 21, 2023 | Portfolio News

FDA Approves LimFlow System in Patients with Chronic Limb-Threatening Ischemia and No Suitable Endovascular or Surgical Revasucularization Options

by Seini Moimoi | Sep 12, 2023 | Portfolio News

Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer

by Seini Moimoi | Sep 11, 2023 | Portfolio News

« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2026 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer